Roivant Sciences Analyst Ratings
Roivant Sciences Analyst Ratings
Buy Rating Justified by Roivant Sciences' Growth Prospects and Strategic Pipeline Expansion
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV)
Buy Rating Justified by Roivant Sciences' Strategic Positioning and Promising Drug Pipeline
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Roivant Sciences Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating
Buy Rating Affirmed for Roivant Sciences Amid Brepocitinib Success and Strategic Share Repurchase Program
Roivant Sciences Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
Roivant Sciences Analyst Ratings
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)